Abstract P3-06-07: ADGRF1 overexpression inhibits tumor growth <i>in vivo</i> by inducing cell cycle arrest in HER2+ breast cancer
Raksha R. Bhat(University of Houston), Meghana V. Trivedi(University of Houston), Rachel Schiff(Baylor College of Medicine), Vidyalakshmi Sethunath(Dana-Farber Cancer Institute), Hariprasad Thangavel(Hackensack Meridian Health), Sarmistha Nanda(Baylor College of Medicine), Hala Yasser(University of Houston), Resel Pereira(Baylor College of Medicine), Noor Mazin Abdulkareem(University of Houston), Lanfang Qin(Pancreatic Cancer Action Network), Martin J. Shea(Baylor College of Medicine), Tamika Mitchell(Baylor College of Medicine), Carmine De Angelis(Baylor College of Medicine)
Cited by 0
Related Papers
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function
|Cancer Research|2008|494
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485